• Markets
    • icon
  • Companies
EYE · ASX

Nova Eye Medical Ltd (ASX:EYE)

AU$0.13

 0.0 (0.0%)
ASX:Live
01/12/2023 04:10:47 PM
Recent Earnings downgrade HALO Ords HALO Consensus Value GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

EYE Overview

EYE Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About EYE

Website

Nova Eye Medical Ltd

Telephone

N/A

Address

107 Rundle Street Kent Town, South Australia (SA) 5067

Description

Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.

EYE Price Chart

Key Stats

Market Cap

AU$26.69M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

100%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.12 - 0.35

Trade Value (12mth)

AU$16,917.00

1 week

0%

1 month

-23.53%

YTD

-57.38%

1 year

-53.57%

All time high

0.731613

Key Fundamentals

EPS 3 yr Growth

101.400%

EBITDA Margin

-56.10%

Operating Cashflow

-$7m

Free Cash Flow Return

-24.10%

ROIC

-54.70%

Interest Coverage

-176.90

Quick Ratio

1.70

Other Data

Shares on Issue (Fully Dilluted)

165m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

EYE Announcements

Latest Announcements

Date Announcements

31 March 23

FDA Clears iTrack Advance for US Launch

×

FDA Clears iTrack Advance for US Launch

31 March 22

EYE Representative Appointed to American Glaucoma Society

×

EYE Representative Appointed to American Glaucoma Society

31 August 20

FY20 Results presentation

×

FY20 Results presentation

30 October 23

Proposed USA Medicare Changes

×

Proposed USA Medicare Changes

30 January 23

Glaucoma Surgical Devices Sales Update

×

Glaucoma Surgical Devices Sales Update

28 November 23

Further Update of Proposed USA Medicare Changes

×

Further Update of Proposed USA Medicare Changes

28 March 23

Notice Of General Meeting

×

Notice Of General Meeting

28 February 22

Notification regarding unquoted securities - EYE

×

Notification regarding unquoted securities - EYE

28 August 23

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

28 August 23

Full Year Financial Results

×

Full Year Financial Results

28 August 23

Appendix 4G

×

Appendix 4G

28 August 23

Investor Presentation 30 June 2023 Results

×

Investor Presentation 30 June 2023 Results

28 April 23

Results of General Meeting

×

Results of General Meeting

27 October 23

Pause in Trading

×

Pause in Trading

27 October 23

Trading Halt

×

Trading Halt

27 November 20

AGM presentation and update

×

AGM presentation and update

27 July 23

Application for quotation of securities - EYE

×

Application for quotation of securities - EYE

27 January 23

Notification of cessation of securities - EYE

×

Notification of cessation of securities - EYE

27 February 23

Trading Halt

×

Trading Halt

26 October 20

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

26 August 22

Appendix 4E and Annual Report FY22

×

Appendix 4E and Annual Report FY22

26 August 22

Results Announcement FY22

×

Results Announcement FY22

26 August 22

Investor Presentation FY22

×

Investor Presentation FY22

26 August 22

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

25 September 23

AGM date and Closing Date for Director Nominations

×

AGM date and Closing Date for Director Nominations

25 October 23

Angle Closure Glaucoma

×

Angle Closure Glaucoma

25 November 22

Application for quotation of securities - EYE

×

Application for quotation of securities - EYE

25 May 22

Notification regarding unquoted securities - EYE

×

Notification regarding unquoted securities - EYE

EYE Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.05 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.05 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37.8 -71.0 -89.4 Lock Lock Lock
     PE X Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.05 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.23 -0.03 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 78.2 -150.9 25.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -71.1 -18.0 -16.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 15.7 N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.25 0.21 0.12 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.16 0.08 0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -74.1 -47.4 -39.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 144 145 156 Lock Lock Lock
Basic m Lock Lock Lock Lock 144 145 156 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 13 13 17 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4.9 -0.1 27.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 7 9 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 2 -1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 207.9 -143.3 210.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock 13.2 -5.7 4.9 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 87 106 95 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -3 -8 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39.9 -133.9 -18.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -25.8 -60.3 -56.1 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -5 -10 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.8 -99.0 -19.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -37.1 -73.9 -69.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -5 -8 -17 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -4 -7 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37.7 -72.1 -104.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -32.5 -56.0 -89.8 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -5 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 2 6 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -3 -5 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -62 0 7 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -13 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -356.1 63.7 -45.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.0 -0.4 -0.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 7 N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 18 8 7 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 42 37 30 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 2 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -14 -6 -6 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 7 6 7 Lock Lock Lock
Equity $m Lock Lock Lock Lock 35 30 23 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 37 32 24 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.6 -14.3 -24.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -10.4 -20.5 -50.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -12.3 -24.7 -65.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -6.9 -27.7 -41.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -6.3 -21.8 -54.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -18.6 -13.6 -24.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -50.7 -126.1 -176.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 4.1 0.8 0.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -39.9 -19.9 -25.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.6 4.0 2.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.0 3.1 1.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 67.6 51.3 50.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -275.3 -121.2 -107.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.9 2.9 5.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 4.0 4.4 4.4 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.6 1.1 2.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 15.0 18.0 25.3 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.4 0.6 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.4 0.6 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -39.2 -61.6 -99.9 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.5 -22.5 -56.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -10.4 -20.5 -50.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -12.3 -24.7 -65.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -12.3 -24.7 -65.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 91.6 83.1 82.8 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 126.1 125.5 73.7 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 217.7 208.6 156.5 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 91.8 54.4 74.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 126.0 154.1 82.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

100%

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

EYE Shortsell

Frequently Asked Questions

The current share price of Nova Eye Medical Ltd (EYE:ASX) is AU$0.13.
The 52-week high share price for Nova Eye Medical Ltd (EYE:ASX) is AU$0.35.
The 52-week low share price for Nova Eye Medical Ltd (EYE:ASX)? is AU$0.12.
Nova Eye Medical Ltd (EYE:ASX) does not pay a dividend.
The last dividend payment of Nova Eye Medical Ltd (EYE:ASX) is AU$2.43.
Nova Eye Medical Ltd (EYE:ASX) has a franking level of 100%.
Nova Eye Medical Ltd (EYE:ASX) is classified in the Healthcare.
The current P/E ratio for Nova Eye Medical Ltd (EYE:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.